`
`
`
`
`
`
`SUPPLEMENT APPROVAL
`
`
`
`
`
`
` Horizon Medicines LLC
`
`
` Attention: Laura Schiavoni, MBA, RAC
` Associate Director, Regulatory Affairs
`
`
`
` 150 S. Saunders Road
` Lake Forest, IL 60045
`
`
`
`
` Dear Ms. Schiavoni:
`
`
`
`
`
` Please refer to your supplemental new drug application (sNDA) dated and received
`
` April 5, 2019, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and
`
`
` Cosmetic Act (FDCA) for VIMOVO (naproxen and esomeprazole magnesium) delayed-
`
`
`
` release tablets.
`
`
`
`
` We also refer to our letter dated March 8, 2019, notifying you, under Section 505(o)(4)
` of the FDCA, of new safety information that we believe should be included in the
`
`
`
` labeling for VIMOVO. This information pertains to a pharmacodynamic study that
` demonstrated interference with the antiplatelet activity of aspirin when naproxen is
`
`
`
` administered with low-dose aspirin.
`
`
`
` This supplemental new drug application provides for revisions to the labeling for
`
`
` VIMOVO, consistent with our March 8, 2019 letter.
`
` APPROVAL & LABELING
`
` We have completed our review of this application It is approved, effective on the date of
`
`
`
`
`
`
`
`
` this letter, for use as recommended in the enclosed agreed-upon labeling.
`
` We note that your July 16, 2019, submission includes final printed labeling (FPL) for
`
`
`
` your Prescribing Information Medication Guide. We have not reviewed this FPL. You
` are responsible for assuring that the wording in this FPL is identical to that of the
`
`
`
` approved content of labeling in the structured product labeling (SPL) format.
`
`
`
`
`
`
`
`
`
`
`
`Reference ID: 4466612
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` NDA 022511-S24
` Page 2
`
`
`
` CONTENT OF LABELING
`
`
`
`
`
` As soon as possible, but no later than 14 days from the date of this letter, submit the
` content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using
`
`
`
`the FDA automated drug registration and listing system (eLIST), as described at
`
` FDA.gov.1 Content of labeling must be identical to the enclosed labeling (Prescribing
` Information, and Medication Guide), with the addition of any labeling changes in
`
`
`
` pending “Changes Being Effected” (CBE) supplements, as well as annual reportable
`
`changes not included in the enclosed labeling.
`
` Information on submitting SPL files using eList may be found in the guidance for
`
`
`
` industry SPL Standard for Content of Labeling Technical Qs and As.2
`
`
`
` The SPL will be accessible from publicly available labeling repositories.
`
` Also within 14 days, amend all pending supplemental applications that include labeling
`
`
`
`
`
` changes for this NDA, including CBE supplements for which FDA has not yet issued an
`
`
`
`
` action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word
`format, that includes the changes approved in this supplemental application, as well as
` annual reportable changes. To facilitate review of your submission(s), provide a
`
`
`
`
` highlighted or marked-up copy that shows all changes, as well as a clean Microsoft
` Word version. The marked-up copy should provide appropriate annotations, including
`
`
`supplement number(s) and annual report date(s).
`
`
` All promotional materials that include representations about your drug product must be
`
` promptly revised to be consistent with the labeling changes approved in this
`
` supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions
`
`
`
` in your promotional materials should include prominent disclosure of the important new
`
`
` safety information that appears in the revised labeling. Within 7 days of receipt of this
`
`
` letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the
`
`
`
`
` address above, by fax to 301-847-8444, or electronically in eCTD format. For more
`
`
` information about submitting promotional materials in eCTD format, see the draft
`
`
`
` guidance for industry Providing Regulatory Submissions in Electronic and Non-
`
`
` Electronic Format-Promotional Labeling and Advertising Materials for Human
`
`
`
`
` Prescription Drugs.
`
` REPORTING REQUIREMENTS
`
`
` We remind you that you must comply with reporting requirements for an approved NDA
`
` (21 CFR 314.80 and 314.81).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` 1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
`
`
` 2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance
`
`
`
` Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
`
`
`
` U.S. Food and Drug Administration
`
`
`
` Silver Spring, MD 20993
`
` www.fda.gov
`
`
`
`
`
`Reference ID: 4466612
`
`
`
`
`
`
` NDA 022511-S24
` Page 3
`
`
`
`
` If you have any questions, call Jacqueline LeeHoffman, PharmD., Safety Regulatory
`
`
` Project Manager, at (240)402-8689.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Sincerely,
`
` {See appended electronic signature page}
`
` Joyce Korvick, M.D., M.P.H.
`
`
` Deputy Director for Safety
` Division of Gastroenterology and Inborn Errors
`
` Products
` Office of Drug Evaluation III
`
` Center for Drug Evaluation and Research
`
`
`
`
`
` ENCLOSURE(S):
`
`• Content of Labeling
`
`
`o Prescribing Information
`
`
`o Medication Guide
`
`
`
`
`
` U.S. Food and Drug Administration
`
`
`
` Silver Spring, MD 20993
`
` www.fda.gov
`
`
`
`Reference ID: 4466612
`
`
`
`Signature Page 1 of 1
`--------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically. Following this are manifestations of any and all
`electronic signatures for this electronic record.
`--------------------------------------------------------------------------------------------
`/s/
`------------------------------------------------------------
`
`JOYCE A KORVICK
`07/22/2019 12:00:00 AM
`
`Reference ID: 4466612
`
`(
`
`
`
`